

BF Biosciences Limited**Condensed Interim Statement of Financial Position**

As at 30 September 2026

	Un-audited 30 September 2026	Audited 30 June 2026
	-----Rupees-----	
EQUITY AND LIABILITIES		
<u>Share capital and reserves</u>		
Authorized share capital 400,000,000 (30 June 2026: 400,000,000) ordinary shares of Rs. 3 each (30 June 2026: Rs. 3 each)	<u>1,200,000,000</u>	<u>1,200,000,000</u>
Issued, subscribed and paid up capital	265,000,002	265,000,002
Share premium	1,780,198,135	1,780,198,135
Unappropriated profit	<u>3,433,775,264</u>	<u>3,248,893,154</u>
	5,478,973,401	5,294,091,291
<u>Non-current liabilities</u>		
Long term loans - secured	960,543,018	1,000,249,410
Long term musharaka - secured	41,043,254	45,302,061
Deferred grant	192,381,031	216,850,368
Deferred taxation	<u>403,645,787</u>	<u>316,989,614</u>
	1,597,613,090	1,579,391,453
<u>Current liabilities</u>		
Current portion of:		
- Long term loans - secured	330,884,841	326,036,865
- Long term musharaka - secured	16,484,767	16,032,110
- Deferred grant	97,352,784	102,091,958
Trade and other payables	1,726,939,736	1,579,171,519
Contract liabilities	103,036,690	42,507,825
Short term borrowings - secured	309,972,270	225,896,547
Mark-up accrued on borrowings	<u>16,937,988</u>	<u>14,714,720</u>
	2,601,609,076	2,306,451,544
	<u>9,678,195,567</u>	<u>9,179,934,288</u>

Contingencies and commitments**ASSETS****Non-current assets**

Property, plant and equipment
Long term advances and deposits
Intangibles

Current assets

Stores, spare parts and loose tools
Stock in trade
Trade debts
Loans and advances
Deposits, prepayments and other receivables
Short term investments
Advance income tax - net
Cash and bank balances

	Un-audited 30 September 2026	Audited 30 June 2026
	-----Rupees-----	
4,873,106,817	4,632,270,644	
96,646,735	94,685,998	
<u>6,378,327</u>	<u>7,229,710</u>	
4,976,131,879	4,734,186,352	
186,233,178	114,346,276	
2,814,957,635	2,938,058,279	
535,688,255	349,484,104	
368,960,120	230,472,173	
91,824,900	59,309,718	
319,175,038	311,074,451	
206,959,448	181,305,119	
<u>178,265,114</u>	<u>261,697,816</u>	
4,702,063,688	4,445,747,936	
9,678,195,567	9,179,934,288	

Chief Executive Officer_____
Chief Financial Officer_____
Director

BF Biosciences Limited**Condensed Interim Statement of Profit or Loss (Un-audited)**

For the period ended 30 September 2026

	First Quarter Ended	
	30 September 2026	30 September 2025
	-----Rupees-----	
Revenue - net	2,783,886,116	2,432,294,309
Cost of goods sold	(1,499,340,983)	(1,393,964,059)
Gross profit	1,284,545,133	1,038,330,250
Administrative expenses	(74,310,457)	(39,852,708)
Selling and distribution expenses	(865,694,768)	(709,174,402)
Other expenses	(29,965,478)	(27,103,847)
Other income	9,512,457	34,849,422
Profit from operations	324,086,887	297,048,715
Finance cost	(30,086,676)	(26,387,010)
Profit before minimum tax differential, final tax and income tax	294,000,211	270,661,705
Minimum tax differential and final tax	-	(2,773,900)
Profit before income tax	294,000,211	267,887,805
Income tax	(109,118,101)	(108,366,370)
Profit after taxation	184,882,110	159,521,435
Earnings per share - basic and diluted	2.09	1.81

Chief Executive Officer_____
Chief Financial Officer_____
Director

BF Biosciences Limited

Condensed Interim Statement of Comprehensive Income (Un-audited)

For the period ended 30 September 2026

	First Quarter Ended	
	30 September 2026	30 September 2025
	-----Rupees-----	
Profit after taxation	184,882,110	159,521,435
Other comprehensive income for the period	-	-
Total comprehensive income for the period	184,882,110	159,521,435

Chief Executive Officer

Chief Financial Officer

Director

BF Biosciences Limited

Condensed Interim Statement of Changes in Equity (Un-audited)

For the period ended 30 September 2026

	Share capital	Capital reserve Share premium	Revenue reserve Unappropriated profit	Total
	----- Rupees -----			
Balance as at 01 July 2025 - audited	265,000,002	1,780,198,135	2,616,766,032	4,661,964,169
Total comprehensive income for the period	-	-	159,521,435	159,521,435
Balance as at 30 September 2025 - un-audited	<u>265,000,002</u>	<u>1,780,198,135</u>	<u>2,776,287,467</u>	<u>4,821,485,604</u>
Balance as at 01 July 2026 - audited	265,000,002	1,780,198,135	3,248,893,154	5,294,091,291
Total comprehensive income for the period	-	-	184,882,110	184,882,110
Balance as at 30 September 2026 - un-audited	<u>265,000,002</u>	<u>1,780,198,135</u>	<u>3,433,775,264</u>	<u>5,478,973,401</u>

Chief Executive Officer_____
Chief Financial Officer_____
Director

BF Biosciences Limited**Condensed Interim Statement of Cash Flows (Un-audited)**

For the period ended 30 September 2026

Cash flow from operating activities

Profit before income tax
Adjustments for non-cash and other items:
Depreciation on property, plant and equipment
Gain on disposal of property, plant and equipment
Amortization
Finance cost
Gain on re-measurement of short term investments to fair value
Gain realized on sale of short term investments
Un-realized exchange gain
Profit on bank deposits
Provision for Workers' Profit Participation Fund
Provision for Central Research Fund
Provision for Workers' Welfare Fund
Minimum tax differential and final tax

Cash generated from operations before working capital changes**Effect on cash flow due to working capital changes**

(Increase) / decrease in current assets
Stores, spare parts and loose tools
Stock in trade
Trade debts
Loans and advances
Deposits, prepayments and other receivables

Increase in current liabilities
Trade and other payables
Contract Liabilities

Cash generated from operations

Taxes paid

Net cash generated from operating activities**Cash flow from investing activities**

Fixed capital expenditure incurred
Proceeds from sale of property, plant and equipment
Short term investments - net
Increase in long term advances and deposits
Profit on bank deposits received

Net cash used in investing activities**Cash flow from financing activities**

Long term loan paid
Long term musharaka paid
Finance cost paid

Net cash used in financing activities**Net decrease in cash and cash equivalents****Cash and cash equivalents at the beginning of the period****Cash and cash equivalents at the end of the period**

Cash and cash equivalents comprise of the following:

Cash and bank balances
Short term borrowings - secured

First Quarter Ended	
30 September	30 September
2026	2025
-----Rupees-----	
294,000,211	267,887,805
74,934,848	66,958,205
(692,307)	(6,250)
851,383	426,803
30,086,676	26,387,010
(7,366,506)	(29,790,774)
(978,775)	(3,051,070)
(12,408)	(992,415)
(386,255)	(1,637,056)
15,789,485	14,536,074
3,189,795	2,936,581
6,000,004	5,523,708
-	2,773,900
121,415,940	84,064,716
415,416,151	351,952,521
(71,886,902)	(1,512,907)
123,100,644	(47,976,845)
(186,217,336)	(387,080,309)
(138,487,947)	(116,059,846)
(32,515,182)	41,468,267
(306,006,723)	(511,161,640)
122,814,526	275,158,171
60,528,865	15,260,496
183,343,391	290,418,667
292,752,819	131,209,548
(48,116,257)	(84,877,693)
244,636,562	46,331,855
(315,782,679)	(64,297,271)
703,965	6,250
244,694	(99,583,786)
(1,960,737)	-
386,255	1,637,056
(316,408,502)	(162,237,751)
(68,309,998)	(68,310,033)
(3,806,150)	(3,023,057)
(23,620,337)	(23,794,338)
(95,736,485)	(95,127,428)
(167,508,425)	(211,033,324)
35,801,269	315,107,595
(131,707,156)	104,074,271
178,265,114	251,121,372
(309,972,270)	(147,047,101)
(131,707,156)	104,074,271

Chief Executive Officer

Chief Financial Officer

Director